Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDUNN trial: long-acting broadly neutralizing antibodies with or without low-dose nivolumab for HIV-1 remission
2025-523725-17-00Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of Teropavimab, zinlirvimab and nivolumab in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Central Denmark Region. Primary endpoint: Time to loss of immunological control of HIV-1 during ATI. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2025-523725-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523725-17-00.